Opinion: A digital option is the right investment for at-home Covid-19 testing
The Biden administration’s recent investment of $230 million to expedite rapid production of the Ellume home Covid-19 test represents an audacious step forward in mitigating the pandemic.
Some experts have criticized it as a “waste of money” because this kit costs more than other alternatives and because of the timing of the investment. I believe the test is worth the extra cost, due to its connectivity and the types of research it enables, though all of these tests need to be evaluated against the other options.
